Press Releases

 
Press Releases
  Date Title and Summary View
Aug 10, 2015
Reached enrollment target of 400 subjects in Phase 3 CHABLIS-SC1 clinical study with blisibimod Additional data on patient-reported outcomes from Phase 2b PEARL-SC blisibimod clinical study presented at EULAR Increased cash position by an incremental $27 million through public offering in July Addition to the Russell 2...
Jul 30, 2015
HAYWARD, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it plans to issue a press release reporting its 2015 second quarter and operational update after the close of the market on Monday, August 10, 2015. About Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmac...
Jul 14, 2015
HAYWARD, Calif., July 14, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise in full by the underwriters of their option to purchas...
Jul 9, 2015
HAYWARD, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock, offered at a price of $7.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and comm...
Jul 8, 2015
HAYWARD, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the ...
Jun 26, 2015
HAYWARD, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, today announced that as of the close of the market on Friday, June 26th, 2015, the Company was added to the Russell 2000® ...
Jun 16, 2015
HAYWARD, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has met the enrollment target of its CHABLIS-SC1 Phase 3 clinical trial evaluating blisibimod for the treatment of lupus. Final data from the trial is expected in the second half of 2016. "Reaching our enrollment target for...
Jun 4, 2015
HAYWARD, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs, today announced that additional data from its Phase 2b PEARL-SC study will be presented in a pos...
May 27, 2015
HAYWARD, Calif., May 27, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs, announced today that Paul F. Truex, President and Chief Executive Officer, will present a corpor...
May 11, 2015
Completed Interim Analysis from Phase 3 Trial with Blisibimod for Systematic Lupus Erythematosus Completed Interim Analysis from Phase 2/3 Trial with Blisibimod for IgA Nephropathy Increased Cash Position by $43 Million Through Equity Investment by Zenyaku and Equity Offering Received $3 Million Research Award from Cys...
Page:
1
... NextLast
= add release to Briefcase
JoomShaper